Exodigm Biosciences Fuels Next-Gen Cell Innovation with $2.3M Investment in Slingshot Biosciences

Exodigm Biosciences is excited to announce a successful funding round in which the company secured $2,300,000, marking a pivotal milestone in its mission to revolutionize cell-based applications. Known for transforming the landscape of cellular research, Exodigm Biosciences—stemming from the innovative legacy of Slingshot Biosciences—continues to be at the forefront of developing robust, scalable, and reproducible cell mimic solutions. With flagship offerings such as TruCytes™ Biomarker controls, SpectraComp® compensation controls, ViaComp® cell health controls, and FlowCytes® instrument controls, the company is setting new benchmarks in precision and efficiency for cell therapy, drug development, diagnostics, and clinical research. This recent infusion of capital is strategically allocated to fuel product innovation, enhance manufacturing capabilities, and drive market expansion initiatives. Investors have recognized that the company’s cutting-edge TruCytes technology, which flawlessly replicates the optical and biochemical properties of real cells without the inherent challenges of traditional controls, fills a critical need in the research community by delivering breakthrough reproducibility, scalability, and cost-effectiveness. The funds will also support efforts to streamline the production process, expand the product line, and establish new collaborations across multi-site validations and regulatory terrains—ultimately accelerating process development and quality control for a host of cell-based assays. This funding milestone not only validates the company's unique approach to cell mimic innovation but also sets the stage for further leadership in the biotech industry. As Exodigm Biosciences looks ahead, the commitment to enhancing research accuracy and reliability remains unwavering, opening up exciting opportunities for researchers and clinicians worldwide. Learn more about how these advancements are reshaping cell-based applications at slingshotbio.com.